Oxidative Stress Assay Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Instrument, Consumables, and Services), By Test Type (Indirect Assays, Antioxidant Capacity Assays, Enzyme Based Assays, and Reactive Oxygen Species Based Assays), By Technology Type (Enzyme-Linked Immunosorbent Assay (Elisa), Flow Cytometry, Chromatography, Microscopy, and Others), By Disease Type (Cardiovascular Disease, Chronic Obstructive Pulmonary Disease (COPD), and Cancer), and Region Forecast 2020-2031

Oxidative Stress Assay Market size was valued at US$ 1,395 million in 2024 and is expected to reach US$ 2,501 million by 2031, growing at a significant CAGR of 8.7% from 2025-2031. The market is the global market for assays and techniques for measuring oxidative stress levels in biological samples. Oxidative stress occurs when there is an imbalance between free radicals (reactive oxygen species) and antioxidants in the body, leading to damage to cells, proteins, and DNA. This imbalance is implicated in various diseases including cancer, cardiovascular diseases, neurodegenerative disorders, and ageing. The upcoming years are likely to witness a notable expansion in the market. This growth is propelled by rising incidence of oxidative stress-related diseases, heightened research and development endeavours by pharmaceutical firms and research institutions, and technological innovations in assays for oxidative stress.

Additionally, supportive efforts by major industry players and governmental organizations to alleviate disease burdens are expected to spur research efforts, consequently boosting the global demand for oxidative stress assays. The anticipated rise in the market is fueled by the growing incidence of diseases correlated with oxidative stress, including cardiovascular diseases, respiratory conditions, oncological disorders, diabetes, and more. A study released by the Institute for Health Metrics and Evaluation in April 2023 revealed a global prevalence of approximately 454.6 million cases of chronic respiratory illnesses such as COPD, pneumoconiosis, asthma, and similar conditions. However, these instruments are equipped with advanced features and functionalities and thus are priced at a premium. For instance, a confocal microscope used in HCS can cost up to US$ 250,000. Additionally, variability and complexity of oxidative stress biomarkers also acts as a restraint of the market.

Key Developments:

• In June 2022, Dojindo, Japan launched the ROS assay kit for photo-oxidation resistant DCFH-DA. DCFH-DA is widely used for reactive oxygen species detection.
• In February 2022, Invitae introduced FusionPlex Dx and LiquidPlex Dx in Europe. FusionPlex Dx is intended to be used as a CDx to aid in identifying patients diagnosed with NSCLC with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusions, and others for whom treatment with targeted therapy may be beneficial.